Coagulopathy Main Factor Covid 19

dc.contributor.authorKayimov Mehriddin Tuymurodovich.
dc.date.accessioned2026-01-01T21:16:02Z
dc.date.issued2023-03-30
dc.description.abstractCoronavirus infection (COVID-19), an acute infectious disease caused by the SARS-CoV-2 virus, is characterized by activation of the hemostasis system, which in the most severe cases can lead to the development of consumption coagulopathy. Coronavirus disease 2019 (COVID-19) in severe cases leads to a cytokine storm, a systemic inflammatory response, and coagulopathy, which is one of the worst prognostic factors. Coagulopathy in COVID-19 is accompanied by a pronounced increase in the level of D-dimer and fibrin/fibrinogen breakdown products, while the deviation of other indicators (prothrombin time, activated partial thromboplastin time, platelet count) at the onset of the disease is relatively rare. This article will consider the role and intensive care of coagulopathy against the background of coronavirus infection
dc.formatapplication/pdf
dc.identifier.urihttps://geniusjournals.org/index.php/erb/article/view/3738
dc.identifier.urihttps://asianeducationindex.com/handle/123456789/67068
dc.language.isoeng
dc.publisherGenius Journals
dc.relationhttps://geniusjournals.org/index.php/erb/article/view/3738/3163
dc.sourceEurasian Research Bulletin ; Vol. 18 (2023): ERB; 178-181
dc.source2795-7675
dc.subjectcoronavirus infection
dc.subjectcoagulopathy
dc.subjectanticoagulant therapy
dc.titleCoagulopathy Main Factor Covid 19
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion
dc.typePeer-reviewed Article

item.page.files

item.page.filesection.original.bundle

pagination.showing.labelpagination.showing.detail
loading.default
thumbnail.default.alt
item.page.filesection.name
tuymurodovich_2023_coagulopathy_main_factor_covid_19.pdf
item.page.filesection.size
252.8 KB
item.page.filesection.format
Adobe Portable Document Format

item.page.collections